NCT05496465View on ClinicalTrials.gov

Safety and Efficacy of Intranasal Epinephrine After Administration of ARS -1 in Subjects With Frequent Urticaria Flares

PHASE2CompletedINTERVENTIONAL
Enrollment

24

Participants

Timeline

Start Date

July 28, 2022

Primary Completion Date

February 29, 2024

Study Completion Date

February 29, 2024

Conditions
Urticaria
Interventions
DRUG

ARS-1

A single treatment of ARS-1.

DRUG

Placebo

A single treatment of placebo nasal spray

Trial Locations (2)

45236

Bernstein Clinical Research Center, LLC, Cincinnati

02114

Massachusetts General Hospital, Boston

Sponsors
All Listed Sponsors
lead

ARS Pharmaceuticals, Inc.

INDUSTRY